India: Medical Device Monitor: March 2017

Last Updated: 20 April 2017
Article by SKP  


The global medical devices market is valued at USD 342.39 billion, out of which India's market accounts for a meagre 1.3% of the total value. The Government of India announced a revised Foreign Direct Investment (FDI) policy for the sector in January 2015 in which foreign investment up to 100% was allowed under the automatic route for both greenfield and brownfield investments. The Reserve Bank of India (RBI) has been mandated by the Ministry of Finance's (MoF's) Financial Intelligence Unit (FIU) to investigate all investments made in the medical devices sector post January 2015 through the automatic route.

The definition of medical devices, for FDI, is the definition as proposed in the Drugs and Cosmetics (Amendment) Bill, 2013. However, the government withdrew this Bill from the Rajya Sabha (Upper House) in June 2016 and released the new Medical Device Rules, 2017 for the sector which will be enforced from 1 January 2018. The Ministry of Health and Family Welfare (MoHFW) is working on a separate legislation to regulate medical devices. The withdrawal of the amendment bill has led to a loophole in the policy as the draft legislation is yet to be enforced and has given the FIU a reason to believe that there could be misrepresentations and companies might invest through the automatic route, even if they are not entitled to do so.

The FIU made these observations post the proposed investment by BioMérieux, a French biotechnology firm, in RAS Lifesciences Private Limited whereby the increase in stake from 60% to 70% came to light.1 Based on the application made to the RBI, BioMérieux believes that it does not need to take approval from the Foreign Investment Promotion Board (FIPB) as the investment was proposed post the withdrawal of the FIPB nod by the government. The RBI agreed with the company and permitted the investment.

Before January 2015, the policy governing FDI in the medical devices sector had three major conditions which were:

  • The foreign investor needs to sign a non-compete clause except with the approval of the FIPB;
  • A certificate along with the FIPB application by the investor and investee is required; and
  • The right to incorporate appropriate conditions for FDI in brownfield investments.

The gap in the policy has the following consequences:

  • After the January 2015 FDI policy announcement, for any foreign investment to qualify under the automatic route, the activity of the company should be confined to manufacturing medical devices and should exclude pharmaceuticals or brownfield pharmaceutical acquisitions.
  • As there is ambiguity over the rules, companies may avail the automatic route, deliberately or otherwise, which they may not be entitled to as the definition under the FDI policy is different from the one effective by law.

To address this issue and avoid hampering any investment while keeping the law as clear as possible, the FIU reached out to the Department of Industrial Policy and Promotion (DIPP) to revisit the FDI policy in consultation with the DoP. The DIPP may issue a notification stating that the definition of medical devices under the FDI policy released in January 2015 will be the definition as prescribed in the Drugs and Cosmetics Act, 1940 and any amendment made to the said act from time to time.2

TÜV SÜD, a German testing and certification company, recently announced a host of different services for medical device manufacturers in India. The aim of these services is to give Indian products global acceptability and exposure, and to provide Indian manufacturers the opportunity to upgrade their products and processes.3


The government of India, over the period of the past 12 months, has been very active on reforms for the medical devices sector. With the introduction of new rules, the government for the first time has defined medical devices separately and has brought the rules up to global standards. The government also took action on the long-standing complaint of overcharging on stents by capping the price, while the consumers are rejoicing the industry is not.

Medical Devices Rules

The ministry released the first draft of rules in July 2016 and post consultation with the industry and stakeholders released the second draft in October 2016. In January 2017, the MoHFW notified the Medical Devices Rules, 20174 and announced that they would be effective from 1 January 2018, thereby providing time for players to adapt to the new rules.5 The rules have been framed to conform to the framework laid down by the Global Harmonization Task Force (GHTF) for medical devices. The rules aim to bring the Indian medical devices industry on par with global standards and have been customised while keeping the Indian context in mind. The major changes made in the rules are:

Definition of medical devices

The 2017 rules define medical devices as follows:

  • Specific devices intended for internal or external use in the diagnosis, treatment, mitigation or prevention of diseases or disorders in human beings or animals which are notified by the government from time to time under the Act. Some categories of devices have already been notified by the government.
  • Specific substances intended to affect the structure or any function of the human body which are not notified by the government. At present, the substances notified are mechanical contraceptives (e.g. condoms, intra-uterine devices, tubal rings) and disinfectants.
  • Surgical dressings, surgical bandages, surgical staples, surgical sutures, ligatures, blood and blood component collection bags with or without anticoagulant.
  • Substances used for in-vitro diagnosis.
  • All substances intended to be used for or in the diagnosis, treatment, mitigation or prevention of any disease or disorder in human beings or animals.

The rules explicitly mention that all devices are regulated which are covered by the definition above, however, the Drugs and Cosmetics Act also include medical devices as part of the definition of the 'drug' and since it has not been amended, the rules will apply to all medical devices. Fortunately, the rules provide clarity and states that in case of confusion/contradictions between the 2017 rules and the Drugs and Cosmetics Act, the 2017 rules will prevail.

Classification of devices

The new rules introduce a rational and scientific approach to the classification, segmenting products based on the risk these devices may pose to human beings. The devices with the lowest risk are class A devices, devices with moderate risk are class B devices, devices with moderately high risk are class C devices and devices with high risk are class D devices. Class A products will not be brought under the purview of any regulation. Class A and class B products consists of X-ray machines, computerised tomography machines, magnetic resonance imaging machines, etc. whereas class C and class D products consists of stents and other implantable devices.

Quality management

With the intention to ensure quality and add quality credence to the Indian medical devices, the rules envision a system wherein third parties can conduct an assessment and certify quality management systems of Class A and B device manufacturers. These certifying bodies have to be accredited by the National Accreditation Board for Certification Bodies (NABCB) to prove their competence with regard to the capability of their human resource. The rules also mention that these third-party bodies can provide assistance to the NABCB for regulating Class C and Class D products. The rules aim to encourage self-certification and hence allow Class A manufacturers to obtain manufacturing licenses before the audit of the facility. However, after getting the approval, an audit has to be conducted by an NABCB accredited body. The rules have empowered state licensing authorities to allocate licenses for Class A and Class B manufacturers. However, the Central Licensing Authority (CLA) will regulate licenses for Class C and Class D manufacturers. The CLA can ask for assistance from experts and other notified bodies on a case to case basis.

Clinical trials

The new rules have separate provisions for the clinical trials of medical devices and these trials will be referred to as clinical investigations. The provisions have eliminated the four-phase stringent trial norms that are applicable for pharmaceuticals and have introduced a two-phase process. Phase one will involve conducting a pilot study on a small focus group to prove the safety and performance. Phase two will be conducted on a larger group. The Central Drugs Standard Control Organization (CDSCO) will regulate the trials of investigative medical devices. Separate provisions for medical management and compensation for the subjects of the trials have been introduced to achieve patient safety. The rules have provided for compensation of up to INR 800,000 for people affected by an adverse trial.

Product standards:

Earlier, there was no clarity of product standards to be followed by medical device manufacturers and there was constant confusion. Medical device manufacturers earlier were in a dilemma as to which BIS (Bureau of Indian Standards) standard to follow for the products. However, the new rules aim to clarify the same and have listed down three standards which are to be followed in the same order and are as follows:

  • A standard notified by the Central government for the medical device specifically or which has been laid down by the BIS or;
  • Where (a) is absent, to a standard laid down by International Organization for Standardization (ISO) or the International Electrotechnical Commission (IEC); or
  • Where both (a) and (b) are absent, the validated manufacturer's standard.


The new rules have eliminated the need for constant re-approval of manufacturing licenses. The licenses have been given indefinite validity, unless the license is suspended, terminated or has been surrendered by the manufacturer. Also, the rules have eliminated the need for applying for a registration certificate at the time of registrating as a foreign manufacturer as well as the need of an import license. Now, the rules specify that a foreign manufacturer only has to appoint an agent in India and then apply for an import license thereby decreasing the time taken to obtain a license. For making the process of approval easy and user-friendly, the entire process can be done online. The rules have capped the shelf-life of medical devices at five years from the date of manufacturing. The rules allow for this shelf-life to be extended provided sufficient evidence is provided by the manufacturer to the CLA to justify the extension. Henceforth, from the applications stage to getting the approval/permission, the process will be online. Also, the rules mention that the National Accreditation Board for Testing and Calibration Laboratories (NABL) along with other agencies will establish laboratories for testing medical devices.

Price ceiling on stents

Coronary stents are used for clearing blockages in coronary arteries. With changing lifestyles, improving access and incomes, and the growth in incidence of chronic diseases like IHD, the number of stent procedures in India has increased significantly and strong growth continues. There are a variety of stents that are sold in the market like bare metal stents, drug-eluting stents, including several newer generation stents. To provide a better perspective, in 2010, approximately 145,000 stent insertion procedures were carried out and in 2015, the number increased to approximately 345,000. With the increase in the number of procedures, the prices of these stents also skyrocketed at the patient level. The government bodies felt that patients and families in general are not able to understand this category well and have been exploited. A report from the National Pharmaceutical Pricing Authority (NPPA) illustrated an analysis of foreign made stents and how they flow through the distribution chain. The report found out that there were profits made by various stakeholders which the report termed as unreasonable. The variance between the landed cost of imported stents and the Maximum Retail Price (MRP) ranged between 300% and 1200%. These margins were inflating the cost of healthcare services drastically because of which these services were unaffordable for many patients.6

The DoP issued a notification in December 2016 stating that a price cap will be imposed on coronary stents so that exploitative pricing can be stopped. The notification would allow the NPPA to ascertain the maximum prices of stents. All coronary, bare metal, drug-eluting stents and subtypes stents such as bioresorbable vascular scaffolds and biodegradable stents are covered under the notification.

By mid-February, the NPPA came out with a formula to regulate the prices of different cardiac stents under two categories: drug-eluting stents and bare metal stents. Accordingly, the NPPA issued a notification stating that the ceiling price of drug-eluting stents and bioresorbable stents will be fixed at INR 29,600 per unit and bare metal stents at INR 7,260 per unit. Para 24 (4) of the Drug Price Control Order (DPCO), 2013 states, "Every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same". After this notification, hospitals have to prepare separate bills for stents (and will not be able to include them in overall procedure/package prices).

The industry has, in general, vigorously opposed the cap. AdvaMed, an international group of device makers, expressed its disappointment with the price cap and said that all stakeholder representations submitted to explain the differentiation between various kinds of stents have been disregarded. The group also suggested that there is a possibility of this step blocking innovation and hampering the sector in the long-run. AiMed, a body representing domestic stent manufacturers, believes that the cap is too harsh and will adversely effect the industry. They believe that the caps need to be reasonable and should allow a smooth transition, and the order, being effective immediately, is not viable.

Doctors have a mixed view on the notification. Dr Vivek Jawali7, chief cardiothoracic and vascular surgeon of Fortis Hospital, believes that the regulation will lead to cheap dumping from China and Canada and FDA approved stents will eventually be withdrawn from the market as they all have been clubbed in a single segment. However, certain hospitals have welcomed the move and will pass the benefit on to the patients. Health experts feel that the average landing price may not exceed INR 17,000 and hence, a price of INR 29,000 still leaves room for profit margins. However, these margins will not sustain R&D and innovation.

There is a possibility that device makers can approach the NPPA to claim higher prices post proving that their technology is better than the existing devices as per the pharmaceutical industry practice.8 However, that might be easier said then done, as a committee of doctors for accessing the essentiality of stents found that there is no clinical data available on deaths or heart attacks on the available drug-eluting stents. It also noted that superiority of bio-absorbable stents is yet to be demonstrated.9 In fact, a study published in the Lancet journal in November 2016 found that bio-absorbable stents, which are touted by many as technologically advanced, posed a higher risk of artery blockage. Thus, it will be critical for the stent makers to prove differentiation in the product on account of technical innovation.

While there have been positive policy initiatives for the industry, the introduction of price control on some devices, and more importantly, the method in which prices are being fixed and regulated are a major hurdle for the industry and have left many participants concerned and confused. In the case of coronary stents, which is the first category of products for which price control has been announced, the following gaps are worrying:

  • No serious and rigorous assessment of the medical technology differences between different kinds of stents and the impact of the same appears to have been done.
  • A better understanding of the price build-up through the entire chain, from supplier to consumer, and how it would affect various stakeholders is needed in this industry. Also, a better assessment should have been made of what margins are required and reasonable through the supply/value chain.
  • Other options to widen access to the underprivileged with lower cost devices and procedures should have been evaluated.
  • More thought as to how to encourage innovation in this industry, where product and technology life cycles are short, is required. It is evident that there needs to be a thorough and proper study conducted by a premier institute like the Indian Council for Medical Research and guide the DoP and NPPA on the appropriate structure. The MTAB10 (Medical Technology Assessment Board), which has been announced but yet to be notified, could be tasked to bring in adequate process and rigour into the technology assessment.

The industry believes that NPPA arrived at the prices in haste and should have conducted more diligence in capping the prices. The NPPA on the other hand believes that the action was due and the public at large should be benefitted with immediate effect. It is clear that while the NPPA's intention is legitimate, the approach to implementation should have been different.

To view the full article click here












The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions